Table 1.
Clinical characteristics at bDMARD initiation in patients with or without CKD progression
| Clinical characteristics | CKD progression (+) (n = 34) | CKD progression (−) (n = 388) | P-value |
|---|---|---|---|
| Age (years) | 67.3 ± 11.3 | 54.0 ± 13.7 | <.001 |
| Female, n (%) | 28 (82.4) | 332 (85.6) | .614 |
| Duration from RA diagnosis to DMARD therapy initiation (months) | 105.1 ± 112.6 | 85.0 ± 92.3 | .234 |
| SS, n (%) | 1 (2.9) | 25 (6.4) | .382 |
| eGFR (mL/min/1.73 m2) | 78.8 ± 12.4 | 86.6 ± 17.3 | .001 |
| Hb level (g/dL) | 11.4 ± 1.7 | 13.5 ± 1.4 | .102 |
| HbA1c (%) | 5.9 ± 1.8 | 5.9 ± 0.8 | .825 |
| LDL-C level (mg/dL) | 109.4 ± 2.2 | 131.0 ± 33.9 | .932 |
| CRP level (mg/dL) | 1.75 ± 2.08 | 1.49 ± 2.37 | .541 |
| CDAI score | 21.7 ± 12.1 | 16.8 ± 12.2 | .029 |
| RF, n (%) | 23 (67.7) | 292 (75.3) | .312 |
| RF titre (U/mL) | 118.1 ± 179.1 | 96.3 ± 128.2 | .355 |
| Anti-CCP, n (%) | 24 (70.6) | 294 (75.7) | .534 |
| Anti-CCP titre (IU/mL) | 62.9 ± 100.3 | 139.9 ± 193.8 | .023 |
| ANA, n (%) | 22 (64.7) | 260 (67.0) | .788 |
| Anti-SSA, n (%) | 17 (8.7) | 40 (10.3) | .588 |
| Treatment | |||
| TNFi, n (%) | 20 (58.8) | 176 (45.3) | .151 |
| Tocilizumab, n (%) | 8 (23.5) | 182 (46.9) | .001 |
| Abatacept, (%) | 7 (20.6) | 30 (7.7) | .002 |
| MTX, n (%) | 27 (79.4) | 306 (78.9) | |
| MTX dose (mg/week) | 8.0 ± 2.4 | 8.7 ± 3.7 | .301 |
| GC, n (%) | 8 (23.5) | 94 (24.2) | |
| GC dose (mg/day) | 5.6 ± 2.1 | 5.1 ± 3.6 | .751 |
| Tacrolimus, n (%) | 5 (14.7) | 34 (8.7) | .226 |
| NSAIDs, n (%) | 12 (35.3) | 64 (16.5) | .010 |
| Anti-diabetic drugs, n (%) | 2 (5.9) | 23 (5.9) | |
| Anti-hypertensive drugs, n (%) | 12 (35.3) | 51 (13.1) | .002 |
| Anti-dyslipidaemia drugs, n (%) | 7 (20.6) | 46 (11.8) | .172 |
| Values during observationa | |||
| Laboratory findings | |||
| Hb level (g/dL) | 12.5 ± 1.7 | 13.8 ± 1.0 | .001 |
| HbA1c (%) | 6.0 ± 0.9 | 5.7 ± 0.4 | .778 |
| LDL-C level (mg/dL) | 110.2 ± 38.1 | 136.2 ± 21.9 | .001 |
| CRP level (mg/dL) | 0.48 ± 0.49 | 0.24 ± 0.29 | <.001 |
| Disease activity | |||
| CDAI score | 6.2 ± 4.1 | 4.7 ± 3.0 | .008 |
| Treatment | |||
| Maximum MTX dose (mg/week) | 8.0 ± 2.4 | 8.8 ± 3.7 | .301 |
| MTX dose at final visit (mg/week) | 2.6 ± 3.0 | 3.8 ± 3.7 | .116 |
| Maximum GC dose (mg/day) | 5.6 ± 2.1 | 5.1 ± 3.6 | .751 |
| GC dose at final visit (mg/day) | 0.4 ± 0.8 | 1.2 ± 2.0 | .270 |
Values are presented as mean ± SD unless stated otherwise. SS, Sjögren syndrome; ANA, anti-nuclear antibody; TNFi, anti-tumour necrosis factor inhibitor; GC, glucocorticoid.
aValues from the baseline to the last observation.